PET-RIMCEB: Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patients A phase III study A randomized, open-label trial comparing intensified immunochemotherapy (Rituximab[R]-MegaCHOP/R-CHOP) with intensified immunochemotherapy (R-MegaCHOP/R-CHOP) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation or observation in early PET negative young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas + A single arm trial of intensified platinum-based immunochemotherapy (R-MegaCHOP/R-Pt-based salvage regimen) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation in early PET positive young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas.

Trial Profile

PET-RIMCEB: Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patients A phase III study A randomized, open-label trial comparing intensified immunochemotherapy (Rituximab[R]-MegaCHOP/R-CHOP) with intensified immunochemotherapy (R-MegaCHOP/R-CHOP) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation or observation in early PET negative young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas + A single arm trial of intensified platinum-based immunochemotherapy (R-MegaCHOP/R-Pt-based salvage regimen) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation in early PET positive young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Melphalan; Prednisolone; Vincristine
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PET-RIMCEB
  • Most Recent Events

    • 20 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top